Welcome to our dedicated page for Anixa Biosciences SEC filings (Ticker: ANIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to track how Anixa Biosciences funds its CER-T ovarian cancer trial or when breast-cancer vaccine data hits the wire? This page brings every Anixa Biosciences SEC filing into one view, updated the moment it posts to EDGAR.
Search engines often send biotech investors here because we answer real questions鈥攍ike 鈥淲here do I find the Anixa Biosciences quarterly earnings report 10-Q filing?鈥� or 鈥淲hich executives bought shares in the latest Anixa Biosciences insider trading Form 4 transactions?鈥�鈥攚ith direct links and plain-English context.
How our AI helps:
- Instant, jargon-free digests that make understanding Anixa Biosciences SEC documents with AI simple.
- AG真人官方-time alerts for Anixa Biosciences Form 4 insider transactions so you never miss management鈥檚 moves.
- Side-by-side trend charts that turn dense R&D spending notes from the 10-K into actionable visuals.
Want the quick version of a 250-page annual report? Our platform offers an Anixa Biosciences annual report 10-K simplified summary that pinpoints cash runway, partnership revenue, and key risk factors. Need fresh numbers between quarters? The AI-layered Anixa Biosciences earnings report filing analysis highlights trial-expense swings inside each 10-Q.
Material event on pipeline data? Dive straight into the Anixa Biosciences 8-K material events explained brief. Curious about pay packages that drive retention? The Anixa Biosciences proxy statement executive compensation section details option grants without legalese.
No more CTRL-F guessing. From Anixa Biosciences executive stock transactions Form 4 to every funding disclosure, Stock Titan鈥檚 AI ensures you spend minutes, not hours, finding what matters.
Xtant Medical Holdings (XTNT) filed an 8-K announcing significant board changes effective 1 Aug 2025. Investment firm Nantahala Capital, now the beneficial owner of 49.1 % of XTNT鈥檚 outstanding shares, requested and secured the appointments of Abhinav 鈥淎bi鈥� Jain and Tyler Lipschultz as independent directors. Jain joins the Compensation and Nominating & Governance Committees; Lipschultz joins the Audit and Compensation Committees.
Jain, an analyst at Nantahala since 2019, brings structured-credit and med-tech investment experience and currently sits on two NASDAQ-listed pharma boards. Lipschultz contributes 35 years of operating leadership in orthobiologics and spine (LocateBio, Orthofix, SeaSpine, NuVasive).
Concurrent with the additions, directors Robert McNamara and Lori Mitchell-Keller resigned; the company states the departures were not due to disagreements but reflected an oral understanding with Nantahala on board composition. Both new directors will receive standard non-employee director compensation and have executed XTNT鈥檚 customary indemnification agreement (Exhibit 10.1).
No other related-party transactions were disclosed beyond the previously reported April 2025 purchase by Nantahala of 57 m shares at $0.42 and associated shelf registration, effective 19 May 2025.
Empro Group Inc. (EMPG) reports the closing of a partial over-allotment exercise linked to its July 2025 IPO. Book-runner R.F. Lafferty & Co. purchased 115,000 additional ordinary shares at the public price of $4.00 on 29 July; settlement occurred 30 July.
The extra shares lift gross IPO proceeds to $5.96 million (pre-underwriting fees and expenses). The company鈥檚 registration statements on Form F-1 (File Nos. 333-282155 & 333-288474) were declared effective 1 July 2025. EMPG ordinary shares have traded on the Nasdaq Capital Market under ticker 鈥淓惭笔骋鈥� since 2 July 2025.
Form 4 filing overview: On 07/11/2025, Anixa Biosciences (ANIX) Chief Executive Officer Amit Kumar executed an open-market purchase (Code 鈥淧鈥�) of 5,000 common shares at $3.15 per share, an aggregate value of roughly $15,750.
Following the transaction, Kumar鈥檚 direct ownership increased to 574,925 shares. No derivative securities were reported and the filing was submitted as a single-person report on 07/14/2025.
The purchase represents a ~0.9% increment to Kumar鈥檚 previously held position and signals a modest vote of confidence from the company鈥檚 most senior executive. However, given the limited dollar amount relative to both his existing stake and the company鈥檚 overall share count, the transaction is unlikely to be viewed as a materially game-changing event by the market.
FAQ
What is the current stock price of Anixa Biosciences (ANIX)?
What is the market cap of Anixa Biosciences (ANIX)?
What is the core focus of Anixa Biosciences Inc?
How does the company鈥檚 CAR-T technology work?
What distinguishes Anixa Biosciences鈥� vaccine portfolio?
Why are strategic collaborations important to the company?
How is safety assessed in Anixa Biosciences鈥� clinical trials?
What competitive advantages does Anixa Biosciences offer in oncology?
How does the company plan to address unmet needs in cancer treatment?
